Compare
Geron Corp vs Standard Biotools Inc. vs Edgewise Therapeutics, Inc. vs Nuvation Bio Inc.
| Latest fiscal year | Geron Corp GERN | Standard Biotools Inc. LAB | Edgewise Therapeutics, Inc. EWTX | Nuvation Bio Inc. NUVB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $85.33M | n/a | $62.90M |
| Revenue growth (YoY) | n/a | -6.2% | n/a | +699.0% |
| Gross margin | n/a | 49.9% | n/a | n/a |
| Operating margin | n/a | -129.2% | n/a | -338.7% |
| Net margin | n/a | -87.8% | n/a | -325.3% |
| Net income | -$83.50M | -$74.90M | -$167.79M | -$204.63M |
| EPS (Diluted) | -$0.13 | -$0.20 | -$1.63 | -$0.60 |
| Operating cash flow | -$111.04M | -$74.34M | -$143.82M | -$173.43M |
| Free cash flow | n/a | -$82.65M | -$144.07M | n/a |
| Cash & equivalents | $77.56M | $120.86M | $61.15M | $164.09M |
| Total assets | $570.54M | $567.75M | $552.60M | $594.82M |
| Total liabilities | $344.67M | $143.46M | $30.35M | $289.11M |
| Shareholders' equity | $225.87M | $424.29M | $522.26M | $305.72M |
| Return on year-end equity | -37.0% | -17.7% | -32.1% | -66.9% |
| Shares outstanding | 639.86M | 386.38M | 106.25M | 337.84M |
Revenue, most recent five fiscal years
| Fiscal year | Geron Corp | Standard Biotools Inc. | Edgewise Therapeutics, Inc. | Nuvation Bio Inc. |
|---|---|---|---|---|
| Latest | $237.0K Ended 2023-12-31 | $85.33M Ended 2025-12-31 | n/a | $62.90M Ended 2025-12-31 |
| 1 year earlier | $596.0K Ended 2022-12-31 | $91.01M Ended 2024-12-31 | n/a | $7.87M Ended 2024-12-31 |
| 2 years earlier | $1.39M Ended 2021-12-31 | $106.34M Ended 2023-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | $253.0K Ended 2020-12-31 | $97.95M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $460.0K Ended 2019-12-31 | $130.58M Ended 2021-12-31 | n/a | n/a |